Anika Responds to CINGAL’s Drug Classification
In late 2015, FDA assigned Anika Therapeutics' CINGAL to the Center for Drug Evaluation and Research (CDER) and not the Center for Device and Radiological Health (CDRH) for its premarket review-a decision with which Anika's leadership says it disagrees. Jan 25, 2016